A comparison of new drugs approved by the FDA, the EMA, and Swissmedic: an assessment of the international harmonization of drugs
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Link
http://link.springer.com/article/10.1007/s00228-018-2431-7/fulltext.html
Reference51 articles.
1. ICH (2017) ICH—harmonization for better health.[24.04.2017]; Available from: http://www.ich.org/home.html
2. Zhang Y, Hueser HC, Hernandez I (2017) Comparing the approval and coverage decisions of new oncology drugs in the United States and other selected countries. J Manag Care Spec Pharm 23(2):247–254
3. Wolfe SM (2013) When EMA and FDA decisions conflict: differences in patients or in regulation? BMJ 347:f5140
4. DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A (2013) Assessment of PRO label claims granted by the FDA as compared to the EMA (2006-2010). Value Health 16(8):1150–1155
5. Alqahtani S, Seoane-Vazquez E, Rodriguez-Monguio R, Eguale T (2015) Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals? Pharmacoepidemiol Drug Saf 24(7):709–715
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Harmonizing regulatory market approval of products with high safety requirements: Evidence from the European pharmaceutical market;Health Economics;2024-03-15
2. Are drug safety measures harmonized? A real-world evidence from three regulatory authorities;Saudi Pharmaceutical Journal;2024-03
3. Therapeutic approaches in proteinopathies;Progress in Molecular Biology and Translational Science;2024
4. A decade comparison of regulatory decision patterns for oncology products to all other non‐oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration;Clinical and Translational Science;2023-07-05
5. Assessment of FDA-Approved Drugs Not Recommended for Use or Reimbursement in Other Countries, 2017-2020;JAMA Internal Medicine;2023-04-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3